Patient Name Mrs. REENA MEENA Lab No 4030812 UHID 40012948 **Collection Date** 13/04/2024 10:04AM 13/04/2024 10:09AM Age/Gender 32 Yrs/Female **Receiving Date Report Date IP/OP Location** O-OPD 13/04/2024 5:36PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

9610450468

BIOCHEMISTRY

Test Name Result Unit **Biological Ref. Range BLOOD GLUCOSE (FASTING)** Sample: Fl. Plasma **BLOOD GLUCOSE (FASTING)** 71 - 109 97 mg/dl

Method: Hexokinase assay.

Mobile No.

Interpretation: -Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

BLOOD GLUCOSE (PP) Sample: PLASMA

BLOOD GLUCOSE (PP) Non - Diabetic: - < 140 mg/dl 110 mg/dl Pre - Diabetic: - 140-199 mg/dl

Diabetic: - >=200 mg/dl

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

THYROID T3 T4 TSH Sample: Serum

Т3	1.340	ng/mL	0.970 - 1.690
T4	7.16	ug/dl	5.53 - 11.00
TSH	1.69	μIU/mL	0.40 - 4.05

RESULT ENTERED BY: NEETU SHARMA

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 1 Of 9

Patient Name	Mrs. REENA MEENA	Lab No	4030812
UHID	40012948	Collection Date	13/04/2024 10:04AM
Age/Gender IP/OP Location	32 Yrs/Female	Receiving Date	13/04/2024 10:09AM
	O-OPD	Report Date	13/04/2024 5:36PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9610450468		

BIOCHEMISTRY

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in thediagnosis of T3-hyperthyroidism the detection of early stages ofhyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

67

1.4 L

5.0

Interpretation: - The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

LFT (LIVER FUNCTION TEST)				Sample: Serum
BILIRUBIN TOTAL	0.41	mg/dl	0.00 - 1.20	
BILIRUBIN INDIRECT	0.26	mg/dl	0.20 - 1.00	
BILIRUBIN DIRECT	0.15	mg/dl	0.00 - 0.30	
SGOT	20.0	U/L	0.0 - 32.0	
SGPT	12.2	U/L	0.0 - 33.0	
TOTAL PROTEIN	7.2	g/dl	6.6 - 8.7	
ALBUMIN	4.2	g/dl	3.5 - 5.2	
GLOBULIN	3.0		1.8 - 3.6	

U/L

Ratio

U/L

35 - 104

1.5 - 2.5

0.0 - 40.0

RESULT ENTERED BY: NEETU SHARMA

ALKALINE PHOSPHATASE

A/G RATIO

GGTP

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 2 Of 9

Patient Name Mrs. REENA MEENA Lab No 4030812 UHID **Collection Date** 13/04/2024 10:04AM 40012948 13/04/2024 10:09AM Age/Gender **Receiving Date** 32 Yrs/Female Report Date O-OPD **IP/OP Location** 13/04/2024 5:36PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 9610450468

BIOCHEMISTRY

BILIRUBIN TOTAL: - Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT: - Method: Diazo method Interpretation: - Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS: - Method: Biver colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder.

ALBUMIN: - Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status.

Cirrhosis, nutritional status.

ALKALINE PHOSPHATASE: - Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE: - Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

LIPID PROFILE

TOTAL CHOLESTEROL	128		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	49.5		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	69.5		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	20	mg/dl	10 - 50
TRIGLYCERIDES	101		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl
CHOLESTEROL/HDL RATIO	3	%	

RESULT ENTERED BY : NEETU SHARMA

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Patient Name Mrs. REENA MEENA Lab No 4030812 UHID 40012948 **Collection Date** 13/04/2024 10:04AM 13/04/2024 10:09AM Age/Gender **Receiving Date** 32 Yrs/Female **Report Date IP/OP Location** O-OPD 13/04/2024 5:36PM

Referred By Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9610450468

BIOCHEMISTRY

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation: -The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method.

Interpretation: -HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease.

LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.

Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are synthesized in the liver.
CHOLESTEROL VLDL: - Method: VLDL Calculative

Interpretation: -High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

UREA	16.40 L	mg/dl	16.60 - 48.50
BUN	8	mg/dl	6 - 20
CREATININE	0.59	mg/dl	0.50 - 0.90
SODIUM	139	mmol/L	136 - 145
POTASSIUM	3.86	mmol/L	3.50 - 5.50
CHLORIDE	107.2 H	mmol/L	98 - 107
URIC ACID	4.3	mg/dl	2.4 - 5.7
CALCIUM	8.94	mg/dl	8.60 - 10.00

RESULT ENTERED BY: NEETU SHARMA

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 4 Of 9

Patient Name Mrs. REENA MEENA Lab No 4030812 UHID **Collection Date** 13/04/2024 10:04AM 40012948 13/04/2024 10:09AM Age/Gender **Receiving Date** 32 Yrs/Female Report Date O-OPD **IP/OP Location** 13/04/2024 5:36PM Referred By Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9610450468

BIOCHEMISTRY

CREATININE - SERUM :- Method: -Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease.

URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.

SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake and kidney reabsorption.

POTASSIUM:- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting renal failure. High level: Debydration, shock severe burns. DKA renalfailure.

renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure.

CHLORIDE - SERUM: - Method: ISE electrode. Interpretation: -Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL: - Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

Sample: WHOLE BLOOD EDTA

HBA1C 5.2 % <5.7% Nondiabetic

5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes

Known Diabetic Patients
< 7 % Excellent Control
7 - 8 % Good Control
> 8 % Poor Control

 ${\tt Method: - Turbidimetric\ inhibition\ immunoassay\ (TINIA)}$

Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbAlC and mean blood glucose values during the preceding 2 to 3 months.

RESULT ENTERED BY : NEETU SHARMA

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 5 Of 9

Patient Name Lab No 4030812 Mrs. REENA MEENA **Collection Date** 13/04/2024 10:04AM UHID 40012948 13/04/2024 10:09AM Age/Gender **Receiving Date** 32 Yrs/Female **Report Date** O-OPD **IP/OP Location** 13/04/2024 5:36PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9610450468

CLINICAL PATHOLOGY

Test Name	Result	Unit	Biological Ref. Range	
URINE SUGAR (POST PRANDIAL)				Sample: Urine
URINE SUGAR (POST PRANDIAL)	NEGATIVE		NEGATIVE	
URINE SUGAR (RANDOM)				Sample: Urine
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	
				Sample: Urine
PHYSICAL EXAMINATION				
VOLUME	20	ml		
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	CLEAR		CLEAR	
CHEMICAL EXAMINATION				
PH	6.0		5.5 - 7.0	
SPECIFIC GRAVITY	1.010		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	TRACE			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	NEGATIVE		NEGATIVE	
MICROSCOPIC EXAMINATION				
WBCS/HPF	1-2	/hpf	0 - 3	
RBCS/HPF	6-8	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	2-3	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	

RESULT ENTERED BY : NEETU SHARMA

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Patient Name Mrs. REENA MEENA Lab No 4030812 UHID 40012948 **Collection Date** 13/04/2024 10:04AM 13/04/2024 10:09AM Age/Gender 32 Yrs/Female **Receiving Date Report Date IP/OP Location** O-OPD 13/04/2024 5:36PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final 9610450468 Mobile No.

CLINICAL PATHOLOGY

NIL **BACTERIA** NIL **OHTERS** NIL NIL

Methodology:-

Methodology:Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific
Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue
(Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method.
interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

RESULT ENTERED BY: NEETU SHARMA

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Patient Name Mrs. REENA MEENA Lab No 4030812 UHID 40012948 **Collection Date** 13/04/2024 10:04AM Age/Gender 13/04/2024 10:09AM **Receiving Date** 32 Yrs/Female Report Date **IP/OP Location** O-OPD 13/04/2024 5:36PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9610450468

HEMATOLOGY

Test Name	Result	Unit	Biological Ref. Range
CBC (COMPLETE BLOOD COUNT)			Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	12.3	g/dl	12.0 - 15.0
PACKED CELL VOLUME(PCV)	41.3	%	36.0 - 46.0
MCV	92.8 H	fl	82 - 92
MCH	27.6	pg	27 - 32
MCHC	29.8 L	g/dl	32 - 36
RBC COUNT	4.45	millions/cu.mm	3.80 - 4.80
TLC (TOTAL WBC COUNT)	6.26	10^3/ uL	4 - 10
DIFFERENTIAL LEUCOCYTE COUNT			
NEUTROPHILS	61.7	%	40 - 80
LYMPHOCYTE	31.6	%	20 - 40
EOSINOPHILS	1.1	%	1 - 6
BASOPHIL	0.5 L	%	1 - 2
MONOCYTES	5.1	%	2 - 10
PLATELET COUNT	1.82	lakh/cumm	1.500 - 4.500

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia.

MCV: - Method: - Calculation bysysmex.

MCH: - Method: - Calculation bysysmex.

MCHC: - Method: - Calculation bysysmex.

MCHC: - Method: - Calculation bysysmex.

REC COUNT: - Method: - Hydrodynamicfocusing.Interpretation: - Low-Anemia, High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method: -Optical Detectorblock based on Flowcytometry. Interpretation: -High-Leucocytosis, Low-

Leucopenia. NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry LYMPHOCYTS :- Method: Optical detectorblock based on Flowcytometry EOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE) 25 H mm/1st hr 0 - 15

RESULT ENTERED BY: NEETU SHARMA

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 8 Of 9

Lab No 4030812 **Patient Name** Mrs. REENA MEENA 13/04/2024 10:04AM UHID 40012948 **Collection Date** 13/04/2024 10:09AM Age/Gender **Receiving Date** 32 Yrs/Female **Report Date** O-OPD **IP/OP Location** 13/04/2024 5:36PM Dr. EHS CONSULTANT **Referred By Report Status** Final Mobile No. 9610450468

Method:-Modified Westergrens. Interpretation:-Increased in infections, sepsis, and malignancy.

End Of Report

RESULT ENTERED BY : NEETU SHARMA

DEPARTMENT OF RADIO DIAGNOSIS

UHID / IP NO	40012948 (11527)	RISNo./Status:	4030812/ Provisional
Patient Name:	Mrs. REENA MEENA	Age/Gender:	32 Y/F
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No:	13/04/2024 9:27AM/ OPSCR24- 25/1237	Scan Date :	
Report Date :	13/04/2024 11:00AM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

ULTRASOUND STUDY OF WHOLE ABDOMEN

Liver: Normal in size & echotexture. No obvious significant focal parenchymal mass lesion

noted. Intrahepatic biliary radicals are not dilated. Portal vein is normal.

Gall Bladder: Lumen is clear. Wall thickness is normal. CBD is normal.

Pancreas: Normal in size & echotexture.

Spleen: Normal in size & echotexture. No focal lesion seen.

Right Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or obstructive

calculus noted.

Left Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or obstructive

calculus noted.

Urinary Bladder: Normal in size, shape & volume. No obvious calculus or mass lesion is seen. Wall

thickness is normal.

Uterus: Normal in size, shape & anteverted in position. Endometrial thickness is normal.

Endometrial cavity is empty. No mass lesion is seen. Cervix is normal.

Both ovaries: Bilateral ovaries are normal in size, shape & volume.

Others: No significant free fluid is seen in pelvic peritoneal cavity.

IMPRESSION: USG findings are suggestive of

• No significant sonographic abnormality noted.

Correlate clinically & with other related investigations.

DR. APOORVA JETWANI

Incharge & Senior Consultant Radiology

MBBS, DMRD, DNB Reg. No. 26466, 16307

DEPARTMENT OF CARDIOLOGY

UHID / IP NO	40012948 (11527)	RISNo./Status:	4030812/
Patient Name:	Mrs. REENA MEENA	Age/Gender:	32 Y/F
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No :	13/04/2024 9:27AM/ OPSCR24- 25/1237	Scan Date :	
Report Date:	13/04/2024 11:21AM	Company Name:	Final

REFERRAL REASON: HEALTH CHCEKUP

2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

M MODE DIMENSIONS: -

Normal Normal								
IVSD	10.4	6-12mm			LVIDS	29.5	20-40mm	
LVIDD	44.9		32-	57mm		LVPWS	16.8	mm
LVPWD	10.4		6-1	l2mm		AO	27.6	19-37mm
IVSS	17.2]	mm		LA	34.0	19-40mm
LVEF	62-64		>	55%		RA	•	mm
	DOPPLER	R MEA	SUREN	IENTS &	& CALC	ULATIONS	<u>:</u>	
STRUCTURE	MORPHOLOGY		VELOC	CITY (m/	's)	GRAD	ENT	REGURGITATION
						(mmHg)		
MITRAL	NORMAL	E	1.12	e'	-	-		NIL
VALVE		A	0.76	E/e'	-			
TRICUSPID	NORMAL	E 0.47		-		NIL		
VALVE			A	0	36	-		
		A 0.36						
AORTIC	NORMAL	1.10			-		NIL	
VALVE								
PULMONARY	NORMAL	0.63					NIL	
VALVE						-		

COMMENTS & CONCLUSION: -

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 62-64%
- NORMAL LV SYSTOLIC FUNCTION
- NORMAL LV DIASTOLIC FUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

IMPRESSION: - NORMAL BI VENTRICULAR FUNCTIONS

DR SUPRIY JAIN MBBS, M.D., D.M. (CARDIOLOGY) **INCHARGE & SR. CONSULTANT** INTERVENTIONAL CARDIOLOGY

DR MEGHRAJ MEENA MBBS, CTCCM, SONOLOGIST **FICC** CONSULTANT PREV. CCU

DR ROOPAM SHARMA MBBS, PGDCC, FIAE CONSULTANT & INCHARGE EMERGENCY, PREV. CARDIOLOGY & INCHARGE CARDIOLOGY(NIC) & WELLNESS CENTER

Patient Name Mrs. REENA MEENA Lab No 669209 UHID 348379 **Collection Date** 13/04/2024 12:07PM 13/04/2024 12:11PM Age/Gender **Receiving Date** 32 Yrs/Female **Report Date IP/OP Location** O-OPD 13/04/2024 2:27PM **Referred By** Dr. EHCC Consultant **Report Status** Final Mobile No. 9773349797

BLOOD BANK INVESTIGATION

Biological Ref. Range Test Name Result Unit

BLOOD GROUPING "O" Rh Negative

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

End Of Report

RESULT ENTERED BY : Dr. NEHA GUPTA Neha Cupts

Dr. NEHA GUPTA MBBS | DIHBT |

INCHARGE BLOOD CENTRE